Summary and opinion by Wendy Anderson.
Two different pharmaceutical companies had their stocks rise by 150% yesterday when they announced that they had successfully treated epilepsy with their cannabis based drugs.
GW Pharmaceuticals and Pennsylvania-based Zynerba Pharmaceuticals both are currently developing and testing several epilepsy treating drugs. One example is Zynerba’s ZYN002, a synthetic cannabinoid that is delivered through the skin via gel. ZYN002 is in phase 1 of testing, which is the earlier phase of testing and is expected to go into phase 2 in the second part of 2016. Phase one is administered to 24 healthy volunteers and 12 epileptic volunteers three doses over a seven day period.
Another drugmaker, Insys, also had a significant rise in their stock by 11.38% due to their cannabis-based drug for epilepsy. The company is well known for it’s cancer pain management drug, Subsys.
My opinion: From the dangerous side effects we have already seen with synthetic cannabis I’m not sure why we can’t just study cannabis in it’s natural form and let it do the healing that way. I guess we can hope for the best for all of the epilepsy sufferers out there and that this doesn’t either turn toxic for their health or get extremely expensive.
Read the original article here.
Comments will be approved before showing up.
Liquid error: Could not find asset snippets/mailchimp-popup.liquid